Drug Trial Radar · NCT06135363
Safety, Tolerability and Pharmacokinetic Study of SC1011 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Nov 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
45
Actual
Start
Aug 11, 2022
Primary completion
Jan 14, 2023
Study completion Jan 14, 2023
Sponsor
- Lead sponsor
- Guangzhou JOYO Pharma Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn about the safety, tolerability and pharmacokinetic profiles of SC1011 in healthy conditions. The main questions it aims to answer are: Safety and tolerability profiles in healthy subjects and pharmacokinetic profiles in healthy subjects. Participants will complete the study including screening period, dosing period, and observation period. Investigators will compare the inhibitory activity of SC1011 tablets with pirfenidone capsules against the same biomarkers(e.g. blood TNFα) to see if they are different between the two drugs.
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
SC1011Drug
SC1011 tablet
Placebo tabletDrug
SC1011-matching placebo tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse events and serious adverse events related drug.Time frame: From baseline to 7 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Xuhui District Central Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.